ScreenerHero

CYCNCyclerion Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · cyclerion.com
3.890USD-5.81%Mkt Cap: 16.84M $P/E: —

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periph…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap16.84M $
Enterprise Value17.36M $
Revenue (TTM)1.90M $
Gross Profit303.00K $
Net Income (TTM)-3.53M $
Revenue/Share0.4900 USD
Last Price3.890 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.11
PEG—
EV/EBITDA—
EV/Revenue9.14
P/S10.03
P/B3.41
EPS (TTM)-1.64
EPS (Forward)-1.31
52W Range
1.02738% of range8.480
52W High8.480 USD
52W Low1.027 USD
Profitability
Gross Margin15.95%
Oper. Margin-359.16%
EBITDA Margin0.00%
Profit Margin-170.11%
ROE-38.83%
ROA-35.33%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.31M $
CapEx (TTM)—
FCF Margin-109.21%
FCF Yield-12.32%
Net Debt-1.39M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.82
Quick Ratio0.76
Book Value/Sh1.195 USD
Cash/Share0.3020 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateMay 16, 2023
Analyst Consensus
Rating—
Target (Mean)8.000 USD
Upside (mean)+105.7%
Target Range8.000 USD – 8.000 USD
# Analysts1
Ownership
Shares Out.4.33M
Float1.24M
Insiders21.70%
Institutions70.86%
Short Interest
Short Ratio2.1d
Short % Float1.14%
Short % Out.0.96%
Shares Short44.97K
Short (prev mo.)49.91K
Technical
SMA 503.544 (+9.8%)
SMA 2002.412 (+61.3%)
Beta1.75
S&P 52W Chg18.16%
Avg Vol (30d)26.50K
Avg Vol (10d)37.89K
Technical Indicators
RSI (14)59.5
MACD0.1254
MACD Signal0.0863
MACD Hist.+0.0390
BB Upper4.071 USD
BB Middle3.653 USD
BB Lower3.235 USD
BB Width22.90%
ATR (14)0.2836 USD
Vol Ratio (20d)2.66x